AIM
AUTL

Aigen Investment Management’s Autolus Therapeutics AUTL Stock Holding History

Aigen Investment Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.5K Buy
+17,837
New +$28K 0.01% 512
2025
Q4 		– Sell
-65,617
Closed -$107K – 593
2025
Q3 		$107K Buy
+65,617
New +$128K 0.02% 734

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Aigen Investment Management's AUTL Position: Q2 2026 in Review

Aigen Investment Management opened a new position in Autolus Therapeutics (AUTL) in Q2 2026: 17,837 shares worth $28.5K. The stake represents 0.01% of the portfolio and ranks #512 among its holdings. This is a return to the name: Aigen Investment Management previously reported a position in AUTL as recently as Q3 2025.

Aigen Investment Management first reported a position in AUTL in Q3 2025 and has held it in 2 quarters since. The position peaked at $107K in Q3 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Aigen Investment Management held 17,837 shares of Autolus Therapeutics worth $28.5K as of Q2 2026.
  • Autolus Therapeutics was a new Aigen Investment Management position in Q2 2026.
  • Autolus Therapeutics made up 0.01% of Aigen Investment Management's portfolio in Q2 2026, its #512 holding.
  • Aigen Investment Management first reported a position in Autolus Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Aigen Investment Management's Autolus Therapeutics position peaked at $107K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.